YungShin Global Holding Corporation (TPE:3705)
55.90
-0.10 (-0.18%)
Aug 28, 2026, 1:30 PM CST
YungShin Global Holding Revenue
YungShin Global Holding had revenue of 1.93B TWD in the quarter ending June 30, 2026, a decrease of -9.20%. This brings the company's revenue in the last twelve months to 7.84B, down -8.43% year-over-year. In the year 2025, YungShin Global Holding had annual revenue of 8.38B with 4.28% growth.
Revenue (ttm)
7.84B
Revenue Growth
-8.43%
P/S Ratio
1.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
14.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.38B | 343.95M | 4.28% |
| Dec 31, 2024 | 8.03B | 1.00B | 14.29% |
| Dec 31, 2023 | 7.03B | -283.83M | -3.88% |
| Dec 31, 2022 | 7.31B | -493.29M | -6.32% |
| Dec 31, 2021 | 7.81B | -279.61M | -3.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.12B |
| Standard Chemical & Pharmaceutical | 7.08B |
| Synmosa Biopharma | 6.68B |
| TTY Biopharm Company | 6.65B |
| ScinoPharm Taiwan | 3.07B |
| Center Laboratories | 1.66B |
| Orient Pharma | 1.52B |
| SCI Pharmtech | 1.26B |